Profile data is unavailable for this security.
About the company
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
- Revenue in USD (TTM)0.00
- Net income in USD-208.94m
- Incorporated2018
- Employees174.00
- LocationDay One Biopharmaceuticals Inc2000 Sierra Point Parkway, Suite 501BRISBANE 94080-1930United StatesUSA
- Phone+1 (650) 484-0899
- Fax+1 (302) 636-5454
- Websitehttps://dayonebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharvaris NV | 0.00 | -115.35m | 1.06bn | 82.00 | -- | 2.71 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.07bn | 173.00 | -- | 2.13 | -- | 12.02 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.09bn | 46.00 | -- | 3.42 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.12bn | 197.00 | 16.69 | 5.06 | 4.69 | 1.98 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.17bn | 278.00 | -- | 4.97 | -- | 5.21 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.19bn | 174.00 | -- | 4.01 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.20bn | 586.00 | -- | 1.06 | -- | 33.52 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| MannKind Corp | 224.60m | 8.49m | 1.26bn | 414.00 | 197.61 | -- | 93.74 | 5.61 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.28bn | 536.00 | -- | -- | -- | 3.59 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.29bn | 171.00 | -- | 2.12 | -- | 62.95 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.30bn | 244.00 | -- | 4.71 | -- | 30.49 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.33bn | 642.00 | 39.66 | 2.94 | 14.15 | 2.56 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.33bn | 85.00 | -- | 2.33 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Data as of May 29 2024. Currency figures normalised to Day One Biopharmaceuticals Inc's reporting currency: US Dollar USD
40.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 7.81m | 8.94% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.63m | 5.29% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.56m | 5.22% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 3.78m | 4.32% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.89m | 3.31% |
| Viking Global Investors LPas of 31 Mar 2024 | 2.56m | 2.93% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.54m | 2.90% |
| Pictet Asset Management SAas of 31 Mar 2024 | 2.38m | 2.72% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.25m | 2.57% |
| Braidwell LPas of 31 Mar 2024 | 2.17m | 2.49% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
